Glucagon like Peptide 1 News and Research

RSS

Could GLP-1 drugs help women with PCOS beyond weight loss?

A scoping review of 28 studies suggests that GLP-1 receptor agonists may improve androgen levels and menstrual function in women with polycystic ovary syndrome (PCOS), alongside their established metabolic benefits. Evidence for improved ovulation, fertility, and pregnancy outcomes remains limited, and the researchers could not determine whether reproductive benefits result directly from the drugs or from weight loss and improved metabolic health.

1 Nov 2026

High-scoring endocrinologists are more likely to prescribe key diabetes drugs

Endocrinologists who scored highest on the American Board of Internal Medicine's Longitudinal Knowledge Assessment (LKA®) were more likely to prescribe a key diabetes drug class following a treatment guidelines update compared to doctors with lower scores.

27 Oct 2026

Millions get GLP-1 drugs through channels insurance records may miss

Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% between March 2024 and October 2025, largely driven by weight-loss indications. They also estimated that approximately one-third of users obtained treatment through nontraditional channels that standard insurance claims may fail to capture.

26 Oct 2026

Semaglutide changes gut bacteria in rats beyond what eating less explains

Researchers compared semaglutide-treated male and female rats with pair-fed animals receiving the same amount and type of food to distinguish drug-associated microbiome changes from those linked to reduced eating. Semaglutide altered bacterial richness and community composition, with some changes absent from the pair-fed groups and uncertain consequences for health.

26 Oct 2026

Nearly three in four popular comfort foods have something in common, researchers find

A US study examining 300 distinct comfort foods identified chips, ice cream, pizza, chocolate, and cookies as the most frequently nominated choices among adults. Researchers found that nearly three-quarters of the foods met hyperpalatability criteria, while approximately 43% were entirely ultra-processed under a strict classification, with relatively small nutritional differences across demographic groups.

22 Oct 2026

Semaglutide and teduglutide reduce immune-driven gut injury in mice

Researchers found that gut-derived GLP-1 and GLP-2 signaling helped protect mice against T cell-induced intestinal injury, with GLP-1R primarily regulating inflammation and GLP-2R supporting intestinal repair. Semaglutide and teduglutide, administered separately or together, reduced acute intestinal damage in mice lacking intestinal proglucagon, suggesting potential avenues for investigating treatments for immune-mediated gut injury.

21 Oct 2026

Could eating whey protein before meals help reduce blood sugar spikes?

A narrative review of 57 randomized trials found that milk and dairy products have inconsistent effects on long-term blood sugar control in adults with type 2 diabetes or prediabetes. Whey protein consumed before meals more consistently reduced short-term blood sugar spikes, but further research is needed to establish whether these benefits persist over time.

19 Oct 2026

Losing weight is one thing. Keeping your muscle is another, experts say

The International Society of Sports Nutrition (ISSN) position stand concludes that sustained calorie restriction drives weight loss, while adequate protein intake and resistance training help preserve lean mass. Reviewing intermittent fasting, ketogenic diets, and other dietary approaches, the authors emphasize individualized nutrition plans, body composition, and sustainable weight management rather than rapid weight loss alone.

14 Oct 2026

Doctors avoided two common words when talking about weight with patients

Researchers analyzed 123 recorded primary care consultations involving adults with type 2 diabetes and elevated BMI, finding that weight was discussed in just 39% of visits. Clinicians avoided potentially stigmatizing terms such as "overweight" and "obesity," while weight-related conversations occurred more frequently among patients taking GLP-1 receptor agonists.

13 Oct 2026

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight over four months after stopping GLP-1 therapy, compared with about 11% under usual care. These exploratory findings suggest structured support may slow early weight regain, but the small sample and short follow-up leave lasting benefits uncertain.

11 Oct 2026

Structured support may slow weight regain after stopping GLP-1 drugs

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors-commonly leading to rapid weight regain.

7 Oct 2026

High-fiber diet beats metformin for blood sugar and weight in trial

High-fiber diet improves blood sugar and weight more than metformin in a small diabetes trial.

7 Oct 2026

Gut mRNA tech supercharges vaccine and GLP-1 delivery

From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go.

5 Oct 2026

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026